Abstract: A flag shape contact includes a substrate, and a plug-in structure for receiving a mating contact. The plug-in structure extends from the substrate in a first direction. A riveting structure is provided for riveting or connecting a wire conductor to the contact. The riveting structure extends from the substrate in a second direction, distinct from the first direction. The riveting structure is disposed outside an extension area of the plug-in structure in the first direction.

Abstract: A flag shape contact includes a substrate, and a plug-in structure for receiving a mating contact. The plug-in structure extends from the substrate in a first direction. A riveting structure is provided for riveting or connecting a wire conductor to the contact. The riveting structure extends from the substrate in a second direction, distinct from the first direction. The riveting structure is disposed outside an extension area of the plug-in structure in the first direction.

Abstract: An engineering design tool and methods for using the same are disclosed. A method may include receiving at least one parent design and generating a plurality of first-generation design copies that each include a characteristic that has mutated from the parent design. New generations of design copies are successively produced from the additional design copies based on fitness testing the new generations of design copies. Characteristics from intergenerational design copies that are not within the same generation are utilized to perform intergenerational crossover, and a likelihood of a mutation of a design copy is increased in response to a threshold number of generations without an improvement in a fitness score of a design copy. New generations continue to be successively produced until a likelihood that any design copy with a higher fitness score will be produced is below a statistical threshold.

Abstract: An engineering design tool and methods for using the same are disclosed. A method may include receiving at least one parent design and generating a plurality of first-generation design copies that each include a characteristic that has mutated from the parent design. New generations of design copies are successively produced from the additional design copies based on fitness testing the new generations of design copies. Characteristics from intergenerational design copies that are not within the same generation are utilized to perform intergenerational crossover, and a likelihood of a mutation of a design copy is increased in response to a threshold number of generations without an improvement in a fitness score of a design copy. New generations continue to be successively produced until a likelihood that any design copy with a higher fitness score will be produced is below a statistical threshold.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The invention pertains to prodrugs of 9-aminomethyl substituted tetracycline compounds, methods of using the compounds, and pharmaceutical compositions containing them.

Abstract: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.

Abstract: Aminomethyl substituted tetracycline compounds, pharmaceutical compositions, and methods of use thereof are discussed.

Abstract: Aminomethyl substituted tetracycline compounds, pharmaceutical compositions, and methods of use thereof are discussed.

Abstract: 10-Substituted tetracycline compounds are described.

Abstract: The invention pertains to prodrugs of 9-aminomethyl substituted tetracycline compounds, methods of using the compounds, and pharmaceutical compositions containing them.

Abstract: The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression.

Abstract: The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression.